Medical World News®: CancerNetwork Discusses mRNA Vaccines With Maurie Markman, MD


During a Deep Dive segment of Medical World News®, CancerNetwork® sat down with Maurie Markman, MD, to discuss how lessons learned from the development of mRNA vaccines for COVID-19 can translate to cancer research.

Since the arrival of mRNA COVID-19 vaccines, new questions have emerged about how science can rally to harness future medical breakthroughs for cancer. mRNA vaccine technology shares similarities with targeted anticancer therapies. Therefore, key lessons from this pandemic could apply to the development of an infrastructure that could mean earlier cancer interventions.

Dr. Maurie Markman, President of Medicine & Science at Cancer Treatment Centers of America, sat down with CancerNetwork® to discuss mRNA vaccines, what we can learn from the development of these products for COVID-19 prevention, and how these lessons can apply to cancer therapies.

This segment comes from the CancerNetwork® portion of the MJH Life Sciences™ Medical World News®, airing daily on all MJH Life Sciences™ channels.

Related Videos
It takes a team of physicians from multidisciplinary backgrounds to best manage patients with contralateral breast cancer, according to a Mayo Clinic Expert.
The presence of several risk factors—such as age, race and mutation status—for contralateral breast cancer must be considered when making treatment decisions, according to an expert from the Mayo Clinic.
Recent study findings related to risk factors for developing contralateral breast cancer may better influence treatment decisions between patients and physicians, according to a Mayo Clinic expert.
An expert from the Mayo Clinic discusses findings from a population-based study concerning germline genetic mutations as risk factors of contralateral breast cancer.
Thus far, findings from 2 trials show that treatment with bipolar androgen therapy is associated with several benefits in patients with castration-resistant prostate cancer, according to an expert from Sidney Kimmel Comprehensive Cancer Center.
An expert from the Mayo Clinic explains why he and his colleagues are researching risk factors for contralateral breast cancer in carriers of moderate-risk genes such as ATM, CHEK2, and PALB2.
Investigators have observed that treatment with bipolar androgen therapy has suppressed at least one oncogene in patients with castration-resistant prostate cancer who derived a response to therapy.
Despite the observed disease-free survival benefit associated with pembrolizumab in high-risk kidney cancer after surgery, the European Association of Urology guidelines maintain a weak recommendation for its use.
Don Dizon, MD, FACP, FASCO, describes the importance of establishing a gender-affirming environment for patients with cancer.
Related Content